Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals
Abraxane Receives New Indication for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer When Curative Surgery or Radiation Therapy Is Not an Option
Lynne Lederman, PhD
Read More
FDA Approvals, Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2012
Read More
FDA Approvals, Payers' Guide
Foreword: The Fourth Annual Payers’ Guide to New FDA Approvals
Read More
FDA Approvals, Payers' Guide
Introduction: New FDA Drug Approvals in 2012: A 15-Year High
Gary M. Owens, MD
Read More
FDA Approvals
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
Lynne Lederman, PhD
Read More
FDA Approvals
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
... .. ...., ....
Read More
FDA Approvals
Belviq: A New Prescription Weight-Loss Treatment for Overweight or Obese Patients
... .. ...., ....
Read More
FDA Approvals
First-in-Class Angiotensin Receptor Neprilysin Inhibitor Promising in Heart Failure with Preserved Ejection Fraction
Mary Mosley
Read More
FDA Approvals
RELAX-AHF: Serelaxin Reduces Dyspnea in Acute Heart Failure
Mary Mosley
Read More
FDA Approvals
GLP-1 Agonism Holds Promise for Preventing Macrovascular Disease in Type 2 Diabetes
Wayne Kuznar
Read More
Page 49 of 53
Results 481 - 490 of 522